\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe European Blockchain Sandbox has opened its third round of calls for innovative use cases involving Distributed Ledger Technologies. Public entities and private sector companies in the European Economic Area, including start up and scale-ups, can now apply for the third cohort of the European Blockchain Sandbox with innovative use case projects.
The Sandbox was launched by the European Commission in 2023 to provide a confidential platform for innovative blockchain use cases involving Distributed Ledger Technologies. It gives projects the chance to engage in discussions with regulators and authorities at both national and EU level. It aims to help projects understand novel regulation issues, increase legal certainty and contribute to the development of best practices.
The European Blockchain Sandbox supports 20 projects annually over a three year period, and is open to use cases across the EU/EEA based on any blockchain infrastructure. Blockchain use cases will be selected based on a number of criteria, including the maturity of their business case and their legal/regulatory relevance and contribution to the EU’s wider policy priorities.
Deadline for applications is 31 January 2025.
More information can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
